William O'Gorman

Appearances

MOLECULAR CHARACTERIZATION OF RESPONSE TO ETROLIZUMAB AND ANTI-TNF REVEALS TREATMENT REFRACTORY ULCERATIVE COLITIS IS ASSOCIATED WITH ABUNDANCE OF RESIDUAL NEUTROPHIL SUBSETS AND ACTIVE FIBROBLAST POPULATIONS
Date
May 19, 2024
BACKGROUND: HIBISCUS I/II assessed the efficacy of etrolizumab versus adalimumab with a 10-week induction regimen in patients with ulcerative colitis (UC)…
Speakers
Shadi Eshghi
John Mark Gubatan
Parisa Mazrooei
Luis Quintanilla
Allen Nguyen
Amelia Au-Yeung
Derek Holman
Courtney Schiffman
William O'Gorman
Chikara Takahashi
Mary Keir
Stephan Rogalla
Jason Hackney
Presenter
Jacqueline McBride